company background image
RDGL

Vivos OTCPK:RDGL Stock Report

Last Price

US$0.074

Market Cap

US$25.3m

7D

9.6%

1Y

-12.0%

Updated

14 May, 2022

Data

Company Financials
RDGL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RDGL Stock Overview

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors.

Vivos Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Vivos
Historical stock prices
Current Share PriceUS$0.074
52 Week HighUS$0.14
52 Week LowUS$0.041
Beta2.13
1 Month Change7.57%
3 Month Change9.08%
1 Year Change-12.02%
3 Year Change130.94%
5 Year Change-92.11%
Change since IPO-99.98%

Recent News & Updates

Shareholder Returns

RDGLUS Medical EquipmentUS Market
7D9.6%-2.3%-2.5%
1Y-12.0%-15.6%-10.4%

Return vs Industry: RDGL exceeded the US Medical Equipment industry which returned -15.6% over the past year.

Return vs Market: RDGL underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is RDGL's price volatile compared to industry and market?
RDGL volatility
RDGL Average Weekly Movement8.8%
Medical Equipment Industry Average Movement10.4%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: RDGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: RDGL's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19941Mike Korenkohttps://www.radiogel.com

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017.

Vivos Fundamentals Summary

How do Vivos's earnings and revenue compare to its market cap?
RDGL fundamental statistics
Market CapUS$25.33m
Earnings (TTM)-US$2.94m
Revenue (TTM)US$27.89k

923.8x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RDGL income statement (TTM)
RevenueUS$27.89k
Cost of RevenueUS$15.00k
Gross ProfitUS$12.89k
Other ExpensesUS$2.95m
Earnings-US$2.94m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0086
Gross Margin46.21%
Net Profit Margin-10,540.69%
Debt/Equity Ratio0.0%

How did RDGL perform over the long term?

See historical performance and comparison

Valuation

Is Vivos undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether Vivos is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vivos has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Vivos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vivos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Vivos performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


25.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RDGL is currently unprofitable.

Growing Profit Margin: RDGL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RDGL is unprofitable, but has reduced losses over the past 5 years at a rate of 25% per year.

Accelerating Growth: Unable to compare RDGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDGL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.4%).


Return on Equity

High ROE: RDGL has a negative Return on Equity (-240.48%), as it is currently unprofitable.


Financial Health

How is Vivos's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RDGL's short term assets ($1.3M) exceed its short term liabilities ($85.5K).

Long Term Liabilities: RDGL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: RDGL is debt free.

Reducing Debt: RDGL currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RDGL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RDGL has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.2% each year.


Dividend

What is Vivos's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RDGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RDGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RDGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RDGL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RDGL has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Mike Korenko (75 yo)

5.42yrs

Tenure

US$262,500

Compensation

Dr. Michael K. Korenko, also known as Mike, Ph D., serves as the Chief Executive Officer and President at Vivos Inc. (formerly known as Advanced Medical Isotope Corporation) and served as its Interim Chief...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD262.50K) is below average for companies of similar size in the US market ($USD771.12K).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RDGL's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: RDGL's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RDGL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

Vivos Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Vivos Inc.
  • Ticker: RDGL
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$25.329m
  • Shares outstanding: 342.74m
  • Website: https://www.radiogel.com

Number of Employees


Location

  • Vivos Inc.
  • 719 Jadwin Avenue
  • Richland
  • Washington
  • 99352
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/14 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.